Antonio Carlos Arrieta
Biography
Antonio Carlos Arrieta, M.D., is Clinical Professor of Pediatrics at UC Irvine School of Medicine and Director of Pediatric Infectious Diseases and Director of Infectious Diseases Clinical Research at CHOC Children's Hospital in Orange, California. He received his medical degree from Universidad Peruana Cayetano Heredia in Lima, Peru, and completed his fellowship in Pediatric Infectious Diseases at Memorial Miller Children's Hospital/University of California, Irvine. From January 2014 to December 2016, he served as President of the CHOC Medical Staff.
Arrieta has served as principal investigator on more than 100 clinical trials evaluating antimicrobial agents, antifungal therapies, and vaccines in pediatric populations. His research has focused on invasive fungal infections in immunocompromised children, pneumococcal disease surveillance following vaccine implementation, and the pharmacokinetics of antimicrobial agents in neonates and infants. He has been principal investigator for multiple Phase 1, 2, and 3 trials of agents including micafungin, voriconazole, isavuconazonium sulfate, ceftolozane/tazobactam, and daptomycin in pediatric patients. His investigator-initiated studies have examined the epidemiology of invasive pneumococcal disease in Orange County following introduction of pneumococcal conjugate vaccines and the use of biomarkers for diagnosis of serious bacterial infections in young infants.
Arrieta is a Fellow of the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society. He has served on multiple guideline development panels for the Infectious Diseases Society of America, including the 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics and the 2023 Guideline on Diagnosis and Management of Acute Bacterial Arthritis in Pediatrics. From October 2013 to November 2015, he served as a member of the Anti-Infective Drugs Advisory Committee for the Food and Drug Administration, and since November 2016 has served as an ad hoc consultant to the Antimicrobial Drugs Advisory Committee. He currently serves as Associate Editor for the journals Children and Frontiers in Pediatrics and is a panel member for the PIDS/IDSA Aspergillosis Guidelines and the IDSA Clinical Practice Guidelines for Septic Arthritis.
Return to topEducation
- MD, Universidad Peruana Cayetano Heredia, 1985
- Residency in Pediatrics, Southern Illinois University
- Fellowship in Pediatric Infectious Diseases, Memorial Miller Children's Hospital/University of California
Distinctions
- Member of the Anti-Infective Drugs Advisory Committee for the Food and Drug Administration, 2013-2015
- Ad hoc consultant to the Antimicrobial Drugs Advisory Committee, 2016
- Fellow of the Infectious Diseases Society (FIDSA), 2012
- Fellow of the Pediatric Infectious Diseases Society (FPIDS), 2021
- Member Fellowship Award Committee for the Pediatric Infectious Diseases Society, 2023-2026
- Member of the Publication Committee for the Pediatric Infectious Diseases Society, 2012-2015
- CHOC Children's Residency Program Teacher of the Year Award, 1993-1994, 1995-1996, 1997-1998, 2003-2004, 2017-2018
- CHOC Children's Outstanding Teacher Award, 1994-1995, 1998-1999, 2014
- OCMA Physician of Excellence Award, 2005-2025
- Best Doctors in Orange County, 2001-2006
Areas of Expertise
- Pediatric Infectious Diseases
- Invasive Pneumococcal Disease
- Antifungal Therapy
- Candidemia Treatment
- Urinary Tract Infections
- COVID-19 Convalescent Plasma
- Antimicrobial Pharmacokinetics
Recent Publications
- Fireizen Y, Ahmed M, Vigers T, Akong K, Ryu J, Hahn A, Fanous H, Koumbourlis A, Tirakitsoontorn P, Arrieta A, “Changing epidemiology of pediatric pulmonary exacerbations in cystic fibrosis.” (opens in new tab), Pediatric Pulmonology, vol. 60, no. 3, pp. e710109, 2025.
- Nieves DJ, Tran T, Singh J, Ashouri N, Morphew T, Lusk J, Adler-Shohet F, Marano R, Osborne S, Strickland J, Arrieta A, “Remdesivir use in pediatric patients with acute SARS-CoV-2 infection is safe and well tolerated.” (opens in new tab), Children, vol. 12, no. 3, pp. 331, 2025.
- Arrieta A, Osborne S, Grant L, Gessner B, Blaschke A, Hulten K, Nieves DJ, Miller A, Bender C, Isturiz R, “Parapneumonic empyema complicating community acquired pneumonia; impact of pneumococcal vaccination and diagnostic role of molecular diagnosis.” (opens in new tab), Pediatric Infectious Disease Journal, vol. 44, pp. 622-629, 2025.
- Lee A, Tran Tuan, Singh J, Arrieta A, “Optimizing voriconazole dosing in extremely premature infants with Aspergillus infections.” (opens in new tab), Pediatric Infectious Disease Journal, 2025.
- Arrieta A, Kovanda L, Engelhardt M, Jones M, Croos-Dabrera R, Sinnar S, Desai A, “A plain language summary of the safety and effectiveness of Isavuconazole for the treatment of serious fungal disease in children with a weakened immune system” (opens in new tab), Expert Review of Anti-Infective Therapy, vol. 23, no. 8, pp. 1-7, 2025.
- Fornari C, Arrieta A, Bradley JS, Tout M, Magalhaes P, Koraichi F, Borella E, Piana C, “Dose rationale for the use of merepenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections.” (opens in new tab), British Journal of Clinical Pharmacology, vol. 90, pp. 2597-2610, 2024.
- Segers H, Deville J, Muller W, Manzanares A, Desai A, Neely M, Bordon V, Hanisch B, Lassaletta A, Fisher B, Autmizguine J, Groll A, Sinnar S, Croos-Dabrera R, Engelhardt M, Jones M, Kovanda L, Arrieta A, “Safety, outcomes, and pharmacokinetics of isavuconazole as treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial.” (opens in new tab), Antimicrobial Agents and Chemotherapy, vol. 68, no. 12, 2024.
- Bucayu R, Boge C, Yildrim I, Aviles-Robles M, Vora S, Berman D, Sharma T, Sung L, Castagnola E, Palazzi D, Danziger-Isakov L, Yin D, Roilides E, Maron G, Tribble A, Soler-Palacin P, Lopez-Medina E, Romero J, Belani K, Arrieta A, “Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network.” (opens in new tab), Journal of the Pediatric Infectious Diseases Society, vol. 13, pp. 633-638, 2024.
- Arrieta A, Galvis A, Osborne S, Morphew T, Imfeld K, Enriquez C, Hoang J, Swearingen M, Nieves DJ, Ashouri N, Singh J, Nugent D, “Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children's Hospital: A Contribution to a Still Inadequate Body of Evidence” (opens in new tab), Children (Basel), vol. 10, no. 2, pp. 350, 2023.
- Arrieta AC, Lee A, Tran MT, “Invasive Mold Infections in Children: Navigating Troubled Waters with a Broken Compass” (opens in new tab), Infectious Diseases and Therapy, vol. 12, no. 6, pp. 1465-1485, 2023.
- Wattier RL, Bucayu RFT, Boge ClK, Ross RK, Yildirim I, Zaoutis TE, Palazzi Dl, Vora SB, Castagnola E, Aviles-Robles M, Danziger-Isakov L, Tribble AC, Sharma TS, Arrieta AC, “Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice from a Multicenter Cohort Study Conducted by the Pediatric Fungal Network” (opens in new tab), Journal of the Pediatric Infectious Diseases Society, vol. 12, no. 9, pp. 487-495, 2023.
- Daniels K, Arrieta A, Nieves D, Bhakta K, Tran T, Osborne S, Morphew T, “Ampicillin and Gentamicin Treatment for Early Onset Neonatal Sepsis: When one Size Does Not Fit All” (opens in new tab), Clin Pediatr (Phila), vol. 62, no. 9, pp. 1027-1031, 2023.
- Bradley J, Goldman J, James L, Kaelin B, Gibson B, Arrieta A, “Pharmacokinetics and Safety of a Single Dose of Telavancin in Pediatric Subjects Aged 2 to 17 Years of Age” (opens in new tab), Antimicrobial Agents and Chemotherapy, vol. 67, no. 11, pp. e0098723, 2023.
- Tran T, Arrieta A, Ashouri N, Frediani J, Lam F, Lin C, “Pharmacogenomics in Patients with Acute Lymphoblastic Leukemia (ALL) to Characterize Vincristine and Triazoles Metabolism”, 2023. Presented at 32nd Annual Pediatric Pharmacy Association meeting, Dallas, Texas, May 3-7, 2023.
- Arrieta A, Segers Heidi, Deville J, Muller W, Manzanares A, Neely M, Bordon V, Hanisch B, Lassaletta A, Fisher B, Autmizguine J, “Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucomycosis in Pediatric Patients.”, 2023. Presented at ID Week 2023, Boston, October 12-14, 2023.
- Stout D, Fireizen Y, Vigers T, Ahmed M, Akong K, Ryu J, Hahn A, Koumbourlis A, Tirakitsoontorn P, Arrieta A, “Trend in Pathogens and Antibiotic Treatment in Children with Cystic Fibrosis in 2018 and 2022: A Retrospective Multicenter Study.”, 2023. Presented at ID Week, Boston, MA, October 13, 2023.
- Arrieta AC, Osborne S, Nieves DJ, Zahn M, Lee A, “Community Acquired Serious Bacterial Infections in Pediatric Patients Before and After COVID: Could masks save lives?”, 2023. Presented at ID Week, Boston, MA, October 13, 2023.
- Bokesch P, Arrieta A, Bradley J, Hoover R, McCurdy S, “PK, Safety and Tolerability of VABOMERE* (mermeropenem-vaborbactam) in Infants, Children and Adolescents”, 2023. Presented at ID Week, Boston, MA, October 13, 2023.
- Daniels K, Arrieta A, Ashouri N, Nieves D, Kushal B, Tran T, Osborne S, Morphew T, Singh J, “Ampicillin and Gentamicin Treatment for Early-Onset Neonatal Sepsis: When One Size does not Fit All.”, 2022. Presented at 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Lisbon, Portugal, April 23-26, 2022.
- Arrieta AC, Blaschke A, Hulten K, Nieves DJ, Osborne S, Grant L, Alexander-Parish R, Gesser B, Isturiz R, Arguedas A, “Culture And Polymerase Chain Reaction (Pcr) For Etiologic Diagnosis Of Community Acquired Pneumonia With Empyema In Children”, 2022. Presented at 12th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD), Toronto, Canada, June 19-23, 2022.
Most Cited Publications
- Wingard J.R., White M.H., Anaissie E., Raffalli J., Goodman J., Arrieta A., “A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia” (opens in new tab), Clinical Infectious Diseases, vol. 31, pp. 1155-1163, 2000.
- Norris A, Shrestha N, Allison G, Keller S, Bhavan K, Zurlo J, Hersh A, Gorski L, Bosso J, Rathore M, Arrieta A, “2018 IDSA Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy” (opens in new tab), Clinical Infectious Diseases, vol. 68, no. 1, pp. 1-4, 2019.
- Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Konja J, Diekmann-Berndt H, Koblinger S, Groll A, Arrieta, A, “Micafungin vs Liposomal Amphotericin B for Pediatric Patients with Invasive Candidiasis: A Randomized Double-Blind trial” (opens in new tab), Pediatric Infectious Disease Journal, vol. 27, no. 9, pp. 820-6, 2008.
- Aliaga S, Clark R, Laughon M, Walsh T, Hope W, Benjamin D, Kaufman D, Arrieta A, “Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units” (opens in new tab), Pediatrics, vol. 133, no. 2, pp. 236-42, 2014.
- Walsh Tj, Drisctoll T, Milligan PA, Wood, Arrieta, A, “Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children” (opens in new tab), Antimicrobial Agents and Chemotherapy, vol. 54, no. 10, pp. 4116-23, 2010.
- Benjamin DK Jr, Huda M, Duara S, Schelonka RL, Bidegain M, Mundakel GT, Shankaran S, Burchfield RD, White K, Shattuck N, Neu N, Bendel C, Kim R, Finer NN, Stewart D, Arrieta AC, “Effect of Fluconazole Prophylaxis on candidiasis and mortality in Premature Infants” (opens in new tab), JAMA, vol. 311, no. 17, pp. 1742-9, 2014.
- Hope WW, Smith PB, Arrieta, A, Buell DN, Roy M, “Population pharmacokinetics of micafungin in neonates and young infants” (opens in new tab), Antimicrobial Agents and Chemotherapy, vol. 54, no. 6, pp. 2633-7, 2010.
- Smith PB, Cohen-Wolkowiez M, Castro L, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, “Population Pharmacokinetics of Meropenem in Plasma and Cerebrospinal Fluid of Infants with Suspected or Complicated Intra-abdominal Infections” (opens in new tab), Pediatric Infectious Disease Journal, vol. 30, no. 10, pp. 844-9, 2011.
- Driscoll T, Yu L, Haydar F, Krance R, Nemecek E, Blumer J, Arrieta, A, “Comparison of Pharmacokinetics and safety of voriconazole intravenous to oral switch in immunocompromised children and healthy adults” (opens in new tab), Antimicrobial Agents and Chemotherapy, vol. 55, no. 12, pp. 5770-9, 2011.
- Aspin MM, Hoberman A, McCarty J, McLinn S, Aronf S, Lang DJ, Arrieta, AC, “A comparative study of the safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children” (opens in new tab), Journal of Pediatrics, vol. 125, no. 1, pp. 136-41, 1994.
Contact Information
Email: arrietaa@uci.edu
Phone: (714) 509-8403
Address: 1201 W. LaVeta Avenue, Orange, CA 92868, Irvine, CA 92868
Return to topThis profile was created with the help of AI.
Last updated on 3/11/2026.